Close Menu

NEW YORK – A little more than a month into its new life as a publicly traded company, sequencing firm Personalis updated investors this week on how customers have been receiving its recently launched comprehensive tumor and immune profiling assay ImmunoID NeXT, as well as how its efforts to develop an exome-wide liquid biopsy product are proceeding.

Launched through an early-access program that began in January, NeXT combines exome-wide analysis of DNA and RNA with interrogation of the tumor microenvironment in a single FFPE sample.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.

Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.

The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.

In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.